View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Gilead Sciences, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Pfizer Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Gilead Sciences Inc: 3 directors

Three Directors at Gilead Sciences Inc sold/sold after exercising options 20,611 shares at between 125.080USD and 127.105USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

Moody's Ratings assigns A2 rating to Pfizer's notes; outlook stable

Moody's Ratings (Moody's) assigned a A2 rating to the new senior unsecured notes offering of Pfizer Inc. (Pfizer). There are no changes to Pfizer's existing ratings including the A2 long-term issuer rating, the A2 senior unsecured notes, the A2 senior unsecured revolving credit facility, or the Prim...

Merck KGaA: Annual update

Our credit view of this issuer reflects its track record of conservative financial policies and solid cash flow generation, constrained by its currently weak late-stage pipeline.

Pfizer Inc.: Update to credit analysis

Our credit view of this issuer reflects its good scale, diversity and pipeline opportunities, weighed against its large patent exposures towards the end of the decade.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...

Moody's Ratings affirms Gilead's A3 rating; revises outlook to positiv...

Moody's Ratings (Moody's) affirmed the ratings of Gilead Sciences, Inc. ("Gilead") including the A3 senior unsecured ratings and (P)A3 senior unsecured shelf rating. At the same time, we revised the outlook to positive from stable. The positive outlook reflects positive momentum in Gilead's pipeli...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch